Exchange: NASDAQ·Updated 07:59 PM EDT

RGNX News

News
all
press releases
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
Mizuho initiated coverage of Regenxbio with an ‘Outperform’ rating and a $22 price target.
Stocktwits
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
Mizuho initiated coverage of Regenxbio with an ‘Outperform’ rating and a $22 price target.
Stocktwits
More News
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingPR...
PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Sept. 8, 2026 ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor...
PR Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February...
Business Wire
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
Zacks
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PR Newswire ROCKVILLE, Md., Aug. 25, 2026 ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc.(Nasdaq: RGNX) today announced the appointment...
PR Newswire
Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.
Stocktwits
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
BofA called the clinical hold on RGX-121 disappointing and a reversal of July’s progress but kept a $15 price target on the stock.
Stocktwits
Why Did RGNX Stock Crash Today?
Regenxbio said the FDA has placed a clinical hold on its Hunter syndrome therapy after the discovery of unusual spine MRI findings in five participants in a study.
Stocktwits
Futures Slide Ahead Of "Pivotal Week" With Nvidia Earnings. Warsh Speech On Deck
Futures Slide Ahead Of "Pivotal Week" With Nvidia Earnings. Warsh Speech On Deck Futures are lower with Tech underperforming as the market focuses on NVDA / MRVL earnings this week; while the AI theme is pressured globally and memory stocks slump driven by a slide in the Kospi. Futures...
Zero Hedge

Advertisement|Remove ads.